https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-10-01 / Front Immunol 2018;9:2265
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-10-01 / Front Immunol 2018;9:22652018-10-01 00:00:002019-02-15 08:36:04Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-10-01 / Am J Clin Dermatol 2018 Oct;19(5):657-670
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-10-01 / Am J Clin Dermatol 2018 Oct;19(5):657-6702018-10-01 00:00:002018-10-01 00:00:00Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-09-07 / Integr Cancer Ther 2018 12;17(4):1297-1303
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-09-07 / Integr Cancer Ther 2018 12;17(4):1297-13032018-09-07 00:00:002019-03-27 11:12:22Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-08-29 / CNS Oncol 2018 07;7(3):CNS22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-08-29 / CNS Oncol 2018 07;7(3):CNS222018-08-29 00:00:002019-02-15 09:00:10Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4 T-lymphocyte counts
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-08-22 / Expert Rev Vaccines 2018 08;17(8):697-705
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-08-22 / Expert Rev Vaccines 2018 08;17(8):697-7052018-08-22 00:00:002019-02-15 08:35:59Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-19 / Oncotarget 2018 Jun;9(47):28702-28716
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-19 / Oncotarget 2018 Jun;9(47):28702-287162018-06-19 00:00:002019-02-15 08:36:18Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-04-20 / Oncol Res Treat 2018;41(5):292-297
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-04-20 / Oncol Res Treat 2018;41(5):292-2972018-04-20 00:00:002020-12-07 09:37:23Immunotherapy of Hepatocellular Carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-05 / J. Clin. Invest. 2018 Apr;128(4):1413-1428
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-05 / J. Clin. Invest. 2018 Apr;128(4):1413-14282018-03-05 00:00:002019-02-15 08:36:17PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-01 / Front Immunol 2018;9:394
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-01 / Front Immunol 2018;9:3942018-03-01 00:00:002019-02-15 08:36:03Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-02-15 / Blood Rev. 2018 Jul;32(4):312-325
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-02-15 / Blood Rev. 2018 Jul;32(4):312-3252018-02-15 00:00:002019-02-15 08:32:43Anti-cancer vaccine therapy for hematologic malignancies: An evolving era
